Provided by Tiger Fintech (Singapore) Pte. Ltd.

MaxCyte Inc

2.82
+0.03001.08%
Post-market: 2.820.00000.00%19:58 EDT
Volume:243.16K
Turnover:689.57K
Market Cap:299.80M
PE:-7.20
High:2.88
Open:2.83
Low:2.80
Close:2.79
Loading ...

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics

MT Newswires Live
·
12 Feb

BRIEF-Maxcyte Says Enters Strategic Platform License With TG Therapeutics

Reuters
·
12 Feb

MaxCyte Signs Strategic Platform License With TG Therapeutics to Advance Its Autoimmune Cell Therapeutics Programs

THOMSON REUTERS
·
12 Feb

MaxCyte Inc - Enters Strategic Platform License With TG Therapeutics

THOMSON REUTERS
·
12 Feb

MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Strategic Platform License With TG Therapeutics

THOMSON REUTERS
·
12 Feb

MaxCyte Inc - TG Therapeutics Obtains Rights to Use MaxCyte Technology

THOMSON REUTERS
·
12 Feb

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

GlobeNewswire
·
07 Feb

MaxCyte Announces Executive Stock Transaction

TIPRANKS
·
31 Jan

Craig-Hallum Gives a Buy Rating to MaxCyte (MXCT)

TIPRANKS
·
30 Jan

MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion

TIPRANKS
·
30 Jan

MaxCyte Acquires Gene Editing Analytics Company SeQure Dx

MT Newswires Live
·
30 Jan

BRIEF-Maxcyte Buys Sequre Dx For $4.5 Million

Reuters
·
30 Jan

MaxCyte Inc - Pays $4.5 Million for Sequre Dx

THOMSON REUTERS
·
30 Jan

MaxCyte Inc - Additional $2.5 Million Contingent on Revenue Targets

THOMSON REUTERS
·
30 Jan

MaxCyte, Inc. MaxCyte, Inc. - Mxcr - MaxCyte® Acquires Sequre Dx

THOMSON REUTERS
·
30 Jan

MaxCyte® Acquires Sequre Dx to Broaden Cell Engineering Offerings With on-Target and off-Target Editing Assessments

THOMSON REUTERS
·
30 Jan

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

GlobeNewswire
·
30 Jan

BlackRock Increases Stake in MaxCyte, Inc.

TIPRANKS
·
29 Jan

Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame

Simply Wall St.
·
29 Jan

MaxCyte Sees Increase in BlackRock Holdings

TIPRANKS
·
22 Jan